2004 : A Randomized, Double-Blind, Placebo- Controlled, Parallel- Group, 8-week, Safety and Efficacy Study of Eszopiclone 3 mg Compared to Placebo in Subjects with Insomnia Related to Major Depressive Disorder. Protocol 190-052, Sepracor, Inc., Marlborough, MA.

2004 : A 12-Month Open Label Evaluation of the Long- Term Safety of DVS- 233 SR in Outpatients with Major Depressive Disorder. Protocol 3151A1-318-US, Wyeth Research Division, Philadelphia, PA.

2004 : A Multicenter, Double- Blind, Placebo- Controlled Comparison of the Efficacy and Safety of Flexible Dose Extended- Release Bupropion Hydrochloride (HCI) 300-450 mg/ day and Placebo Administered for Eight Weeks for the Treatment of Adult Outpatients with Major Depressive Disorder and Symptoms of Decreased Energy, Pleasure, and Interest. Protocol AK130931, GlaxoSmithKline, Research Triangle Park, NC.

2003 : A Multicenter, Randomized, 8-month, Placebo-Controlled, Double-Blind Study for the Evaluation of Comparative efficacy between Duloxetine and Escitalopram in Patients with Major Depression. Protocol F1J-US-HMCR(a), Eli Lilly and Company, Indianapolis, IN.

2003 : A Double Blind, Multicenter Study Evaluating the Efficacy and Safety of One Fixed Dose of SR58611A (700 mg/day) Versus Placebo and Paroxetine (20 mg/day) in Patients with a Recurrent Major Depressive Episode. Protocol EFC5379, Sanofi-Synthelabo, Malvern, PA.

2003
: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of three Fixed Doses (100mg, 200mg, or 400mg) of DVS-233 SR In Adult Outpatients with Major Depressive Disorder. Protocol 3151A1-306-US, Wyeth Research Division, Philadelphia, PA.

2003 : A 10-month, Open Label Evaluation of the long-Term Safety of DVS-233 SR in Outpatients with Major Depressive Disorder. Protocol 3151A1-303-WW, Wyeth Research Division, Philadelphia, PA.

2003 : A Double-Blind, Multicenter, Randomized, Placebo-Controlled Efficacy and Safety Study of Org 33062 ER in Subjects with Major Depressive Disorder. Protocol FKGBE008, Fabre-Kramer Pharmaceuticals, Inc., Houston, TX

2003 : A 4-week, Double-Blind, Randomized, Multicenter, Fixed Dose, Placebo-Controlled, Parallel Group Study of Lorazepam and Paroxetine in Patients with Generalized Anxiety Disorder: Assessment of a New Instrument Intended to Capture Rapid Onset. Protocol A9001141, Pfizer Global Research and Development, Ann Arbor, MI.

2003 : Validation of Daily Telephone Self-Assessment in the Study of Antidepressant Treatment Outcome. Protocol H8I-MC-HQAC(a), Eli Lilly and Company, Indianapolis, IN

2003 : A 6-Week, Randomized, Double-Blind, Parallel-Group Active- and Placebo-Controlled Trial to Assess the Efficacy of R228060 in Adult Subjects With Major Depressive Disorder (MDD). Protocol R228060-MDD-201 Phase 2a, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ.

2003 : A Double-Blind, Multicenter, Placebo- and Active-Controlled Acute and Extension Study of 2 Doses of MK-0869 in the Treatment of Patients with Major Depressive Disorder. Protocol 062-03, Merck & Co., Inc., Whitehouse Station, NJ.